Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma

Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma

Abstract Background Current standard of care for advanced biliary tract cancer (BTC) is gemcitabine, cisplatin plus anti‐PD1/PD‐L1, but response rates are modest. The purpose of this study was to explore the efficacy and safety of durvalumab (anti‐PD‐L1) and tremelimumab (anti‐CTLA‐4), with and with...

Full description

Bibliographic Details
Main Authors: Cecilia Monge, Changqing Xie, Yuta Myojin, Kelley L. Coffman‐D'Annibale, Donna Hrones, Gagandeep Brar, Sophie Wang, Anuradha Budhu, William D. Figg, Maggie Cam, Richard Finney, Elliot B. Levy, David E. Kleiner, Seth M. Steinberg, Xin Wei Wang, Bernadette Redd, Bradford J. Wood, Tim F. Greten
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Cancer Medicine
Subjects:
biliary tract cancer
cholangiocarcinoma
cryoablation
durvalumab
immune checkpoint inhibitor
interventional radiology
Online Access:https://doi.org/10.1002/cam4.6912

Internet

https://doi.org/10.1002/cam4.6912

Similar Items